This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
MRM Health NV is a clinical-stage biopharmaceutical company that develops microbiome-based live biotherapeutic products for the treatment of chronic inflammatory diseases and to augment immune-oncology therapies. Founded in 2019 as a spin-off from the Flanders Institute for Biotechnology (VIB) and Ghent University.[1][2][3] MRM Health is developing MH002, a microbial consortium candidate for the treatment of ulcerative colitis, and operates a proprietary co-fermentation platform CORAL.[4]
History
editThe technology underlying MRM Health originates from microbiome research carried out in Ghent. ProDigest, founded in 2008 by Sam Possemiers, developed in vitro gut models and strain‑selection methods that informed the rational design of microbial consortia.[5][6] MRM Health was established in 2019 as a translational spin‑off from VIB and Ghent University to advance these discoveries toward clinical development.[7][8][9]
In 2019, the company completed a Series A financing round of approximately €14 million, with participation from Ackermans & van Haaren (AvH), DuPont Nutrition & Biosciences (now IFF), OMX Europe Venture Fund (comprising Korys and Merieux Equity Partners), and company management.[10][11]
In 2020 MRM Health entered a collaboration with DuPont Nutrition & Biosciences (later IFF) to explore microbiome solutions for metabolic disease programs.[12][13]
In 2025, the company closed a €55 million Series B financing round led by Biocodex, with new investors also including Athos and BNP Paribas Private Fortis Equity. It announced a strategic development and manufacturing agreement with Biocodex to support clinical development and scale-up of its CORAL platform.[14][15][16][17]
Research and technology
editMRM Health develops live biotherapeutic products composed of defined bacterial consortia that are intended to restore microbial balance, strengthen intestinal barrier function, and modulate immune responses.[18] The company’s proprietary CORAL platform enables co‑fermentation of multiple bacterial strains in a single process, producing a homogeneous drug substance intended to be scalable and manufacturable to GMP standards.[19][20]
MH002
editMH002 is MRM Health’s lead programme: a rationally designed six-strain microbial consortium developed for the treatment of ulcerative colitis. The product is intended to restore a healthy gut microbial balance, reinforce the intestinal barrier and rebalance immune activity without broad immunosuppression.[21][22] Early clinical studies including Phase 2a trials in ulcerative colitis and the orphan condition pouchitis reportedly demonstrated a favorable safety profile and preliminary signs of efficacy.[23][24]
Other programs
editBeyond MH002, MRM Health is developing additional consortia for Crohn’s disease and metabolic disorders, and exploring applications to enhance cancer immunotherapies (immune‑oncology).[25] The company also maintains research activities in animal health in collaboration with partners. Several preclinical and IND‑enabling programmes are reported to be in development.[26]
References
edit- ↑ Zain, Sharmain (2025-05-06). "ProDigest: the truth behind the gut". ProDigest. Retrieved 2025-11-25.
- ↑ "The Flemish Institute for Biotechnology (VIB)". PROTrEIN (in Spanish). Retrieved 2025-11-25.
- ↑ "ProDigest customized solutions in gut microbiome research". 2020-07-22. Retrieved 2025-11-25.
- ↑ Vanneste, Lies (2025-09-04). "MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline". VIB Press. Retrieved 2025-11-25.
- ↑ "SHIME® digests food and drugs just like humans do | NLO". www.nlo.eu. Retrieved 2025-11-25.
- ↑ "ICA Forum 2012 — Possemiers" (PDF). ICA Europe. Retrieved 21 October 2025.
- ↑ Vanneste, Lies (2025-06-25). "MRM Health – Redefining Microbiome Therapeutics". VIB Blog. Retrieved 2025-11-25.
- ↑ "MRM Health – Company Profile & Funding Rounds". Tracxn. Retrieved 21 October 2025.[failed verification]
- ↑ "DuPont joins forces with MRM Health to develop microbiome-based therapeutic solutions". www.nutritioninsight.com. Retrieved 2025-11-25.
- ↑ "MRM Health–Ackermans & van Haaren: investment, 202509 financing round Series B totalling €55m incl existing + co-investor AvH - [LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal". www.life-sciences-benelux.com. Retrieved 2025-11-25.
- ↑ Heles, Thierry (2020-02-21). "MRM Health embeds $15m -". Retrieved 2025-11-25.
- ↑ Read, 11 Min (2020-02-20). "MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences and boosts its development with an investment of more than €14 million to redefine microbiome-based therapeutics". BioSpace. Retrieved 2025-11-25.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ↑ Chu, Will (2020-02-20). "DuPont carries on microbiome momentum with metabolic disease collaboration". NutraIngredients.com. Retrieved 2025-11-25.
- ↑ Vanneste, Lies (2025-09-04). "MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline". VIB Press. Retrieved 2025-11-25.
- ↑ "MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline | AFP.com". www.afp.com. Retrieved 2025-11-25.
- ↑ Times, Microbiome (2025-09-04). "MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline - Microbiome Times Magazine". Retrieved 2025-11-25.
- ↑ "MRM Health raises €55 million Series B to advance best-in-class microbiome-based biotherapeutic product pipeline". Financial Post. 21 October 2025. Retrieved 21 October 2025.
- ↑ "MRM raises $64M for 'high performance teams of bacteria' in IBD | BioWorld". www.bioworld.com. Retrieved 2025-11-25.
- ↑ "Information Technology | The Mind Research Network (MRN)". www.mrn.org. Retrieved 2025-11-25.[failed verification]
- ↑ "MRM Health - redefining microbiome therapeutics". mrmhealth.com. Retrieved 2025-11-25.
- ↑ "MRM Health Secures €55 Million in Series B Financing to Propel Microbiome-Based Therapeutics - SynBioBeta". www.synbiobeta.com. Retrieved 2025-11-25.
- ↑ "MRM Health Secures €55 Million Series B to Advance Microbiome-Based Therapeutics for Inflammatory Diseases". MedPath. 2025-09-04. Retrieved 2025-11-25.
- ↑ "MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis | Business Wire". kommunikasjon.ntb.no (in Norwegian). Retrieved 2025-11-25.
- ↑ "MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002 | Business Wire". kommunikasjon.ntb.no (in Norwegian). Retrieved 2025-11-25.
- ↑ "MRM Health presents its proprietary microbiome therapeutics optimisation and manufacturing technology at the Microbiome Movement Drug Development Conference · Korys". Retrieved 2025-11-25.[failed verification]
- ↑ "MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)". Neuro Central. 2024-05-15. Retrieved 2025-11-25.